The GLP-1 Paradox: The Breakthrough Is Working. The System Isn’t

The GLP-1 revolution is reshaping obesity care, revealing how primary care economics and reimbursement gaps leave patients ...

Novo Nordisk, United Laboratories 'triple G' drug trial shows 19.7% weight loss

COPENHAGEN, Feb 24 (Reuters) - Novo Nordisk and United Laboratories International said on Tuesday a Chinese mid-stage trial ...

Verdiva Bio Announces Completion of Enrollment for EVOLVE-2 Phase 2b Study of VRB-101, a Potential Once-Weekly Oral GLP-1 Peptide Analog in Individuals with Obesity

Verdiva Bio Limited ("Verdiva Bio" or "the Company") a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, today announced ...
News24

Obesity medicines, like Ozempic, are needed in SA’s public sector. Can our government provide them?

In South Africa, access to weight loss medicines like Ozempic and Mounjaro remains limited to those who can shell out a few thousand rand a month.

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...
PharmaTimes

Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101

Verdiva Bio has completed enrolment for its phase 2b EVOLVE‑2 clinical study of VRB‑101, a once‑weekly oral GLP‑1 peptide analog being developed for body‑weight reduction in people with overweight or ...
News-Medical.Net on MSN

Higher ultra-processed food intake aligns with greater binge eating risk in obesity study

By Tarun Sai Lomte New clinical research links ultra-processed food consumption with disordered eating patterns and poorer diet quality in adults with obesity, highlighting potential targets for ...

Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...
The Manila Times

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achie…

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of ...

Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS ...